NNIT - Full-Service IT Consultancy White Papers

Business is dynamic - so why should content management be static? In this article, I present an emerging and radically new approach to content management. This approach focusses not solely on content, but on the context of that content. I claim that this approach not only modernises and optimises the use of business documentation, but also dramatically reduces the costs of validating content management systems in pharmaceutical companies. This confirms Gartner's conclusion that context-aware computing generally provides significant competitive advantages.
View white paper
How to Design a Clinical Data Warehouse The Source Data Mapping (SDM) module includes one mapping design (ETL) for each source from which the CDW is loading, thereby replacing several of the 'foundation' CDW features described above. How static or dynamic the ETL needs to be depends on the level of flexibility and variation in the data source. If data are sourced from a Clinical Data Management (CDM) system, there will be variations in how the trials are defined and structured. In this case, one should consider making the source data mapping dynamic and letting the SDM handle any necessary data conversion.
View white paper
10 tips for selecting the best Commercial Off The Shelf (COTS) software product Selecting a Commercial Off The Shelf (COTS) software product is usually a demanding process. Not only does it require clear objectives and goals, but also a dedicated group of key stakeholders with substantial business process insight. Moreover, to ensure the process is successfully planned and completed, it's necessary to use a transparent method to document decisions and capture learnings and decisions.
View white paper
Go Digital or Die What is the raison d'être for pharmaceutical companies? An ethical one would be that pharmaceutical companies must develop innovative products that make a difference for people. An improvement at even the smallest margins potentially translates into prolonged life or improved quality of life. So we measure at more and more delicate margins - hoping to discover the one magical compound in the alchemist's kitchen that has the potential to make a difference - and to become a blockbuster. Because, let's be honest: regardless of the noble work we are not in philanthropy. It's also tough business. Every day preceding the launch of a new drug is an investment. Eventually shareholders crave value for money.
View white paper
CRM for Life Sciences The pharmaceutical market is undergoing radical change and companies are forced to restructure their commercial organisations to face the new market needs and new business models. Increasing market restrictions and new stakeholders representing a change of decision power are some of the challenges.
View white paper